Mesoblast Limited (MSB.AX)
| Previous close | 0.9150 |
| Open | 0.9250 |
| Bid | 0.9750 x 1092600 |
| Ask | 0.9300 x 5097500 |
| Day's range | 0.8900 - 0.9500 |
| 52-week range | 0.2550 - 1.3511 |
| Volume | |
| Avg. volume | 9,875,864 |
| Market cap | 1.061B |
| Beta (5Y monthly) | 2.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings date | 29 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.60 |
Simply Wall St.Three Leading Growth Companies In Australia With Insider Ownership Reaching 27%
As the Australian market navigates through fluctuating bond yields and anticipates potential interest rate hikes, investors are closely monitoring various economic indicators and corporate activities. Amid these conditions, companies with high insider ownership can be particularly intriguing, as such ownership might align management's interests more closely with those of shareholders, potentially fostering greater resilience and long-term strategic focus during uncertain times.
ZacksMesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
Mesoblast (MESO) gains as the FDA states that the available phase III data for lead candidate, remestemcel-L, is sufficient to support a regulatory filing for pediatric SR-aGVHD indication.
BenzingaAfter Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
Monday, the FDA informed Mesoblast Limited (NASDAQ:MESO) that following additional consideration, the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA) for remestemcel-L for pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD). “We thank the agency for their collaborative approach. The responses and guidance from FDA are clear and provide us with a high level of
